215
Participants
Start Date
December 9, 2021
Primary Completion Date
March 31, 2027
Study Completion Date
January 31, 2031
4D-150 IVT
4D-150: AAV-based gene therapy comprised of miRNA targeting VEGF-C and codon-optimized sequence encoding aflibercept
Aflibercept IVT
Commercially available Active Comparator Other Name: Eylea
RECRUITING
Mid Atlantic Retina, Bethlehem
RECRUITING
Cumberland Valley Retina Consultants, Hagerstown
WITHDRAWN
Western Carolina Retinal Associates, Asheville
RECRUITING
Palmetto Retina Center, LLC, West Columbia
RECRUITING
Retinal Specialty Institute, Pensacola
RECRUITING
Vitreo Retinal Associates, Gainesville
RECRUITING
Florida Eye Associates, Melbourne
RECRUITING
Rand Eye Institute, Deerfield Beach
RECRUITING
Retina Vitreous Associates of Florida, Tampa
RECRUITING
Tennessee Retina, Nashville
RECRUITING
Retina Partners Midwest, Carmel
RECRUITING
University Retina and Macula Associates, Oak Forest
WITHDRAWN
Retina Consultants of Texas, The Woodlands
RECRUITING
Valley Retina Institute, PA, McAllen
RECRUITING
Austin Clinical Research, Austin
RECRUITING
Colorado Retina Associates, Lakewood
RECRUITING
Barnet Delaney Perkins Eye Center, Phoenix
RECRUITING
Sierra Eye Associates, Reno
RECRUITING
California Retina Consultants, Oxnard
RECRUITING
Retinal Consultants Medical Group, Sacramento
RECRUITING
Verum Research, LLC, Eugene
WITHDRAWN
Pacific Northwest Retina LLC, Bellevue
RECRUITING
Ophthalmic Consultants of Boston & Boston Eye Surgery and Laser Center, Boston
RECRUITING
Emanuelli Research and Development Center, LLC, Arecibo
Lead Sponsor
4D Molecular Therapeutics
INDUSTRY